Experimental drug duo aims to boost immune attack on tough cancers

NCT ID NCT07707895

First seen Jul 16, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the two-drug combo, and the second adds a third drug (a checkpoint inhibitor) to see if the combination is tolerable and can stop cancer growth. Participants receive the drugs as infusions and are monitored for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of two experimental drugs: obrixtamig and ZL-1310, sometimes with atezolizumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced neuroendocrine cancers, potentially slowing tumor growth.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits and risks are not yet well understood. The combination may cause significant side effects or may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA OF LARGE CELL HISTOLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amsterdam UMC Locatie VUMC

    Amsterdam, 1081HV, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CTR Leon Berard

    Lyon, 69373, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Charité - Universitätsmedizin Berlin

    Berlin, 13354, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, 2050, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Freeman Hospital

    Newcastle upon Tyne, NE7 7DN, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Guy's Hospital

    London, SE1 9RT, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • HOP Timone

    Marseille, 13385, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hokkaido Cancer Center

    Hokkaido, Sapporo, 003-0804, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Clinico De Valencia (INCLIVA)

    Valencia, 46010, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Duran i Reynals

    L'Hospitalet Del Llobregat, 08908, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Gustave Roussy

    Villejuif, 94800, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Kansai Medical University Hospital

    Osaka, Hirakata, 573-1191, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Leicester Royal Infirmary

    Leicester, LE1 5WW, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Lower Silesian Oncology Centre

    Wroclaw, 53439, Poland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Robert Bosch Gesellschaft für medizinische Forschung mbH

    Stuttgart, 70376, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Chest Hospital

    Shanghai, 200030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Pulmonary Hospital

    Shanghai, 200433, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shizuoka Cancer Center

    Shizuoka, Sunto-gun, 411-8777, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • St. Marianna University Hospital

    Kanagawa, Kawasaki, 216-8511, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza

    Brzozów, 36-200, Poland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Affiliated Cancer Hospital, Guangxi Medical University

    Nanning, 530021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitair Ziekenhuis Antwerpen

    Edegem, 2650, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitair Ziekenhuis Gent

    Ghent, 9000, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Kentucky Medical Center

    Lexington, Kentucky, 40536, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, 55131, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.